
AstraZeneca names controversial cancer scientist José Baselga to a top R&D post in major shakeup
Just days after Bahija Jallal announced her decision to leave her post at the top of AstraZeneca’s big biologics subsidiary MedImmune and take the helm at Immunocore, the pharma giant is shaking up its R&D leadership and bringing in a controversial new head of oncology R&D.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.